2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …
F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
Racial and ethnic disparities in peripheral artery disease
EL Hackler III, NM Hamburg… - Circulation research, 2021 - Am Heart Assoc
Peripheral artery disease is an obstructive, atherosclerotic disease of the lower extremities
causing significant morbidity and mortality. Black Americans are disproportionately affected …
causing significant morbidity and mortality. Black Americans are disproportionately affected …
[PDF][PDF] 2016 ESC/EAS guidelines for the management of dyslipidaemias
AL Catapano, I Graham, G De Backer… - Polish Heart …, 2016 - journals.viamedica.pl
5.1. Wpływ stylu życia na stężenie cholesterolu całkowitego i stężenie cholesterolu frakcji
lipoprotein o małej gęstości................................ 1259 5.2. Wpływ stylu życia na stężenie …
lipoprotein o małej gęstości................................ 1259 5.2. Wpływ stylu życia na stężenie …
Underuse of prevention and lifestyle counseling in patients with peripheral artery disease
JS Berger, JA Ladapo - Journal of the American College of Cardiology, 2017 - jacc.org
Background: Little is known about patterns of medication use and lifestyle counseling in
patients with peripheral artery disease (PAD) in the United States. Objectives: The authors …
patients with peripheral artery disease (PAD) in the United States. Objectives: The authors …
A review of the pathophysiology and potential biomarkers for peripheral artery disease
Peripheral artery disease (PAD) is due to the blockage of the arteries supplying blood to the
lower limbs usually secondary to atherosclerosis. The most severe clinical manifestation of …
lower limbs usually secondary to atherosclerosis. The most severe clinical manifestation of …
[PDF][PDF] 2016 ESC/EAS guidelines for the management of dyslipidaemias
MT Cooney, E Bruckert, A Cordero, A Corsini… - European heart …, 2016 - iris.unime.it
The content of these European Society of Cardiology (ESC) and European Atherosclerosis
Society Guidelines has been published for personal and educational use only. No …
Society Guidelines has been published for personal and educational use only. No …
[HTML][HTML] Ten year mortality in different peripheral arterial disease stages: a population based observational study on outcome
F Sartipy, B Sigvant, F Lundin, E Wahlberg - European Journal of Vascular …, 2018 - Elsevier
Objective The aim was to determine long-term mortality rates and the underlying cause of
death for subjects with different peripheral arterial disease (PAD) stages in a population …
death for subjects with different peripheral arterial disease (PAD) stages in a population …
Polyvascular disease and risk of major adverse cardiovascular events in peripheral artery disease: a secondary analysis of the EUCLID trial
JA Gutierrez, H Mulder, WS Jones… - JAMA network …, 2018 - jamanetwork.com
Importance The effect of polyvascular disease on cardiovascular outcomes in the
background of peripheral artery disease (PAD) is unclear. Objective To determine the risk of …
background of peripheral artery disease (PAD) is unclear. Objective To determine the risk of …
SIRT1 as a therapeutic target in diabetic complications
J Strycharz, Z Rygielska, E Swiderska… - Current medicinal …, 2018 - ingentaconnect.com
Background: Sirtuin1 is an epigenetic enzyme involved in histone and nonhistone protein
deacetylation. It acts primarily as a metabolic sensor, which responses to changing energy …
deacetylation. It acts primarily as a metabolic sensor, which responses to changing energy …
Enhancement of functionality and therapeutic efficacy of cell-based therapy using mesenchymal stem cells for cardiovascular disease
CW Yun, SH Lee - International journal of molecular sciences, 2019 - mdpi.com
Cardiovascular disease usually triggers coronary heart disease, stroke, and ischemic
diseases, thus promoting the development of functional failure. Mesenchymal stem cells …
diseases, thus promoting the development of functional failure. Mesenchymal stem cells …